Literature DB >> 19091563

Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.

Y von Coburg1, T Kottke, L Weizel, X Ligneau, H Stark.   

Abstract

Histamine H3 receptor (H3R) antagonists have some antipsychotic properties although the clear molecular mechanism is still unknown. As actually the most effective and less side effective antipsychotics are drugs with multiple targets we have designed typical and atypical neuroleptics with an additional histamine H3 pharmacophore. The 4-(3-piperidinopropoxy)phenyl pharmacophore moiety has been linked to amitriptyline, maprotiline, chlorpromazine, chlorprothixene, fluphenazine, and clozapine. Amide, amine and ester elements have been used generally to maintain or slightly shift affinity at dopamine D(2)-like receptors (D2 and D3), to decrease affinity at histamine H(1) receptors, and to obtain H3R ligands with low nanomolar or subnanomolar affinity. Change of effects at D(1)-like receptors (D1) and (D5) were heterogeneous. With these newly profiled compounds different antipsychotic properties might be achieved.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19091563     DOI: 10.1016/j.bmcl.2008.09.012

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  17 in total

Review 1.  Multiple Targeting Approaches on Histamine H3 Receptor Antagonists.

Authors:  Mohammad A Khanfar; Anna Affini; Kiril Lutsenko; Katarina Nikolic; Stefania Butini; Holger Stark
Journal:  Front Neurosci       Date:  2016-05-30       Impact factor: 4.677

2.  Evaluation of AaDOP2 receptor antagonists reveals antidepressants and antipsychotics as novel lead molecules for control of the yellow fever mosquito, Aedes aegypti.

Authors:  Jason M Conley; Jason M Meyer; Andrew B Nuss; Trevor B Doyle; Sergey N Savinov; Catherine A Hill; Val J Watts
Journal:  J Pharmacol Exp Ther       Date:  2014-10-20       Impact factor: 4.030

3.  Bodilisant-a novel fluorescent, highly affine histamine h3 receptor ligand.

Authors:  Miriam Tomasch; J Stephan Schwed; Alexander Paulke; Holger Stark
Journal:  ACS Med Chem Lett       Date:  2012-12-12       Impact factor: 4.345

Review 4.  Schizophrenia: synthetic strategies and recent advances in drug design.

Authors:  Maria Azmanova; Anaïs Pitto-Barry; Nicolas P E Barry
Journal:  Medchemcomm       Date:  2018-03-16       Impact factor: 3.597

5.  LC-MS-MS Method for the Analysis of New Non-Imidazole Histamine H(3) Receptor Antagonist 1-[3-(4-tert-Butylphenoxy)propyl]piperidine in Rat Serum-Application to Pharmacokinetic Studies.

Authors:  Malgorzata Szafarz; Joanna Szymura-Oleksiak; Dorota Lazewska; Katarzyna Kiec-Kononowicz
Journal:  Chromatographia       Date:  2011-02-25       Impact factor: 2.044

6.  DOGS: reaction-driven de novo design of bioactive compounds.

Authors:  Markus Hartenfeller; Heiko Zettl; Miriam Walter; Matthias Rupp; Felix Reisen; Ewgenij Proschak; Sascha Weggen; Holger Stark; Gisbert Schneider
Journal:  PLoS Comput Biol       Date:  2012-02-16       Impact factor: 4.475

7.  Anticonvulsant effects of isomeric nonimidazole histamine H3 receptor antagonists.

Authors:  Bassem Sadek; Ali Saad; Johannes Stephan Schwed; Lilia Weizel; Miriam Walter; Holger Stark
Journal:  Drug Des Devel Ther       Date:  2016-11-07       Impact factor: 4.162

8.  Predicting drug-target interactions by dual-network integrated logistic matrix factorization.

Authors:  Ming Hao; Stephen H Bryant; Yanli Wang
Journal:  Sci Rep       Date:  2017-01-12       Impact factor: 4.379

Review 9.  Drug Design for CNS Diseases: Polypharmacological Profiling of Compounds Using Cheminformatic, 3D-QSAR and Virtual Screening Methodologies.

Authors:  Katarina Nikolic; Lazaros Mavridis; Teodora Djikic; Jelica Vucicevic; Danica Agbaba; Kemal Yelekci; John B O Mitchell
Journal:  Front Neurosci       Date:  2016-06-10       Impact factor: 4.677

Review 10.  Current Enlightenment About Etiology and Pharmacological Treatment of Autism Spectrum Disorder.

Authors:  Nermin Eissa; Mohammed Al-Houqani; Adel Sadeq; Shreesh K Ojha; Astrid Sasse; Bassem Sadek
Journal:  Front Neurosci       Date:  2018-05-16       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.